Government of Nepal has an obligation to ensure availability of affordable and high quality basic health care services to its population
Weekly epidemiological recordRelevé épidémiologique hebdomadaire 29 JULY 2016, 91th YEAR / 29 JUILLET 2016, 91e ANNÉENo 30, 2016, 91, 349–364
The recommendations cover the level of blood pressure to start medication, what type of medicine or combination of medicines to use, the target blood pressure level, and how often to have follow-up checks on blood pressure. In addition, the guideline provides the basis for how physicians and other h...ealth workers can contribute to improving hypertension detection and management.
more
Update, 23 de junio de 2022
27 September 2022
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This position paper on polio vaccines replaces the 2016 WHO position paper, and summarizes recent developments in the field.
Guía de tratamiento farmacológico y manejo deescenarios clínicos de casos de COVID-19 – enero 2022 Guía de tratamiento farmacológico y manejo deLeer más
orientaciones provisionales, primera publicación: 24 de mayo de 2021, actualización: 21 de octubre de 2021, actualización: 15 de marzo de 2022
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat...ed: version 15 March 2022.
more
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th...is document has been updated: version 15 March 2022.
more
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been ...updated: version 15 March 2022.
The vaccine is formulated from an inactivated SARS-CoV-2 antigen and is presented in single dose vials and multidose vials of 5, 10 and 20 doses.
more
O SAGE aplica os princípios da medicina baseada em evidências e estabeleceu um processo metodológico completo para emitir ou atualizar recomendações. Especificamente para vacinas contra a COVID-19, uma descrição detalhada dos processos metodológicos pode ser encontrada no esquema de evidênc...ias do SAGE para vacinas contra a COVID-19. Esse esquema contém orientações sobre como levar em consideração os dados provenientes de ensaios clínicos em apoio à emissão de recomendações baseadas em evidências específicas para vacinas.
more
Esta orientação provisória foi desenvolvida com base na recomendação emitida pelo Grupo Consultivo Estratégico de Especialistas (SAGE) em imunização, em sua reunião extraordinária de 5 de janeiro de 2021, e atualizada durante sua reunião extraordinária de 27 de maio de 2021 (2), sendo no...vamente atualizada em 19 de novembro de 2021 e em 19 de janeiro de 2022. Foram coletadas as declarações de interesses de todos os colaboradores externos, sendo elas avaliadas quanto a quaisquer conflitos de interesse. Os resumos dos interesses relatados podem ser encontrados no site da reunião do SAGE e no site do Grupo de Trabalho do SAGE. A orientação se baseia em evidências resumidas no documento de referência sobre a vacina de mRNA BNT162b2 (Pfizer-BioNTech) contra COVID-19 (4), sendo novamente atualizado com base em novos dados provenientes de publicações científicas.
more
orientations provisoires, première publication : 8 janvier 2021, mise à jour : 15 juin 2021, mise à jour : 19 novembre 2021, mise à jour : 21 janvier 2022
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir...st issued 8 January 2021, updated 15 June 2021, updated 19 November 2021, updated 21 January 2022, updated 18 August 2022. Available in other languages https://apps.who.int/iris/handle/10665/361720
more
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).